A simple high-performance liquid chromatographic assay for concurrent quantification of lumefantrine and efavirenz in human plasma from malaria–HIV co-infected individuals

Abstract

BackgroundAs per current treatment guidelines, artemether-lumefantrine and efavirenz-based antiretroviral therapy are recommended drugs for falciparum malaria and human immunodeficiency virus (HIV) infections, respectively. A liquid chromatography-ultraviolet detection method for simultaneous quantification of lumefantrine and efavirenz was developed and validated for efficacy and pharmacokinetic clinical studies. Lumefantrine and efavirenz were separated using a 100 x 4.6 mm x 3 & mu;m Fortis C-18 chromatographic column, and a multistep gradient mobile phase. Calibration curves were obtained with a series of standard solutions containing known concentrations of the chemical reference of both analytes prepared concomitantly in drug-free plasma. The assay was validated within the calibration ranges of 78.125-20,000 ng/mL for lumefantrine and 187.15-24,000 ng/mL for efavirenz. Stability assessment was carried out with or without heating the quality control sample to 58 & DEG;C for 45 min. The method was employed to measure the plasma concentrations of lumefantrine and efavirenz in a study conducted among malaria-HIV co-infected patients.ResultLumefantrine and efavirenz were well separated from each other and from the biological matrix. The method demonstrated a good recovery of 72.64% for lumefantrine and 117.17% for efavirenz. The intra- and inter-day accuracy presented as 95.36-105.14% for lumefantrine and 104.11-115% for efavirenz and precision ranged from 1.15 to 6.45% for lumefantrine and 0.43 to 13.12 for efavirenz, were within & PLUSMN; 15% at the three quality control levels. The analytes from both quality control lots and samples collected from HIV-malaria co-infected individuals were found to be stable post-deactivation of infectious virus by heating to 58 & DEG;C for 45 min.ConclusionThe assay is accurate, precise and shown to simultaneously measure the lumefantrine and EFV in human plasma. PU - SPRINGER PI - NEW YORK PA - ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES